A nurse is caring for a client who had chorionic villus sampling (CVS) performed at 12 weeks’ gestation and asks when she can expect results from this test.

The nurse should inform her that results are typically available within which timeframe?

This is because a nuchal translucency ultrasound measures the amount of fluid behind the baby’s neck in the first trimester of pregnancy, which can indicate the risk of having a chromosomal condition like Down syndrome.

Some possible explanations for the other choices are:

Choice A is wrong because fetal growth and development are not directly related to the nuchal translucency measurement.

Fetal growth and development are assessed by other parameters such as crown-rump length, biparietal diameter, abdominal circumference, etc.

Choice B is wrong because blood flow in the umbilical cord is not measured by the nuchal translucency ultrasound.

Blood flow in the umbilical cord is assessed by Doppler ultrasound, which evaluates the resistance and velocity of blood flow in the umbilical artery and vein.

Choice D is wrong because structural abnormalities in the baby’s organs are not detected by the nuchal translucency ultrasound.

Structural abnormalities in the baby’s organs are diagnosed by a detailed anatomy scan, which is usually performed in the second trimester of pregnancy.

The normal range for nuchal translucency is between 1 mm and 3 mm.

A measurement above 3 mm is considered increased and may indicate a higher risk of chromosomal or genetic conditions.

However, a nuchal translucency ultrasound is a screening test and not a diagnostic test, so it does not confirm or rule out any condition.

It only provides a probability based on statistical calculations.

Therefore, further testing may be recommended if the nuchal translucency measurement is increased or if other risk factors are present.

This test can detect genetic disorders.

Chorionic villus sampling (CVS) is a prenatal test that involves taking a sample of tissue from the placenta to test for chromosomal abnormalities and certain other genetic problems.

The placenta is a structure in the uterus that provides blood and nutrients from the mother to the fetus.

Choice A is wrong because CVS does not provide information on neural tube defects, such as spina bifida.

For this reason, women who undergo CVS also need a follow-up blood test between 16 to 18 weeks of their pregnancy to screen for neural tube defects.

Choice C is wrong because CVS can detect chromosomal abnormalities, but not all chromosomal abnormalities are genetic disorders.

For example, Down syndrome is a chromosomal abnormality that occurs randomly and is not inherited from the parents.

Choice D is wrong because CVS cannot detect Rh sensitization, which is a condition where the mother’s immune system produces antibodies against the fetus’s blood cells.

Rh sensitization can be detected by a blood test that measures the level of antibodies in the mother’s blood.